✦ LIBER ✦

Lenalidomide is active for extramedullary disease in refractory multiple myeloma

✍ Scribed by Tomonori Nakazato; Ai Mihara; Chisako Ito; Yukinari Sanada; Yoshinobu Aisa

Publisher: Springer
Year: 2011
Tongue: English
Weight: 97 KB
Volume: 91
Category: Article
ISSN: 0939-5555
DOI: 10.1007/s00277-011-1272-6

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Lenalidomide is effective as salvage the

Lenalidomide is effective as salvage therapy in refractory or relapsed multiple myeloma: analysis of the Spanish Compassionate Use Registry in advanced patients

✍ Adrián Alegre; Beatriz Aguado; Pilar Giraldo; Eduardo Ríos; Araceli Cánovas; Áng 📂 Article 📅 2011 🏛 Carden Jennings Publishing 🌐 English ⚖ 832 KB

Combined pegylated liposomal doxorubicin

Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy

✍ Pieter Sonneveld; Roman Hajek; Arnon Nagler; Andrew Spencer; Joan Bladé; Tadeusz 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 137 KB

## Abstract ## BACKGROUND Recently, the authors reported improved time to disease progression (TTP) with a combination of pegylated liposomal doxorubicin (PLD) and bortezomib compared with bortezomib alone in a phase 3 randomized trial in patients with recurrent/refractory multiple myeloma (MM). I

Signaling status of IgG B cell receptor

Signaling status of IgG B cell receptor (IgG BCR) is indicative for an activated state of circulating B cells in multiple myeloma

✍ Vesna Ilić; Nadežda Milošević-Jovčić; Sonja Petrović; Dragana Marković; Jelena B 📂 Article 📅 2007 🏛 Springer 🌐 English ⚖ 364 KB

sICAM-1 is not a marker for disease acti

sICAM-1 is not a marker for disease activity in the relapse-free interval of multiple sclerosis - a cross-sectional pilot study

✍ Peter Flachenecker; Stefan Jung; Peter Rieckmann; Klaus V. Toyka 📂 Article 📅 2002 🏛 Springer 🌐 English ⚖ 227 KB